Dublin, Jan. 18, 2016 (GLOBE NEWSWIRE) -- Research and Markets (http://www.researchandmarkets.com/research/53xptt/world_market_for) has announced the addition of the "World Market for Prescription Dermatological Drugs, 9th Edition (Anti-acne, Anti-aging, Dermatitis, Hair Loss, Psoriasis, Skin Cancer, Melasma and Seborrhea Treatments)" report to their offering.
The worldwide market for prescription dermatological drugs encompasses a wide variety of products that treat disorders of the skin as well as the effects of aging. It's a very dynamic time for the prescription dermatological drug industry. Consolidation, economic times, new technologies and genetic discoveries are among the trends that the industry is seeing.
The field of dermatology is currently experiencing a busy and interesting period and, as a result, the range of therapeutic options available to physicians has expanded.This Kalorama Information report, The Worldwide Market for Prescription Dermatological Drugs represents the ninth time that Kalorama has detailed the various categories of prescription dermatological drugs, describing the global market and identifying major market factors that may help to shape the market for treatments in the future.
The driving forces for this market include growth and aging of the worldwide population, new products and technologies, and focus on lifestyle treatments that improve the effects of aging and damage to the skin. Within the pharmaceutical industry as a whole, financial depression, consolidation and economic downturns have influenced the market.
The following companies are profiled in this report:
- Allergan Inc.
- Allergan Inamed Corporation
- Barrier Therapeutics, Inc
- Bayer AG
- PharmaDerm Pharmaceuticals, Inc
- Bristol-Myers Squibb
- Collagenex (now Galderma) Pharmaceuticals
- Galderma S.A.
- Genentech, Inc.
- GlaxoSmithKline Plc
- Johnson & Johnson (Janssen Pharmaceutica, Ortho Dermatological, Ortho-McNeil)
- Medicis Pharmaceutical Corporation
- Merck & Company, Inc.
- Mylan Pharmaceuticals, Inc,
- Novartis Pharmaceuticals Corporation
- Nycomed Inc.
- Pfizer, Inc.
- Q-Med AB
- Roche Group (F. Hoffmann-La Roche Ltd.)
- Schering (now Merck)-Plough Corporation
- Sinclair Pharma Plc.
- SkinMedica
- Stiefel Laboratories, Inc.
- Valeant Pharmaceuticals, Inc.
Key Topics Covered:
Chapter One: Executive Summary
Chapter Two: Introduction
Chapter Three: Issues And Trends
Chapter Four: Prescription Antiacne And Rosacea Drugs
Chapter Five: Prescription Antiaging And Photodamage Drugs
Chapter Six: Prescription Dermatitis And Seborrhea Drugs
Chapter Seven: Prescription Antifungal Drugs
Chapter Eight: Prescription Hair Loss And Hair Removal Drugs
Chapter Nine: Prescription Hyperpigmentation/Melasma And Depigmenting Drugs
Chapter Ten: Prescription Psoriasis Drugs
Chapter Eleven: Prescription Skin Cancer Drugs
Chapter Twelve: Miscellaneous Skin Disorder Drugs
Chapter Thirteen: World Market Summary
Chapter Fourteen: Corporate Profiles
For more information visit http://www.researchandmarkets.com/research/53xptt/world_market_for
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Healthcare and Medical Devices, Pharmaceuticals, Skin Cancer


Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 



